Immunovant
IMVT
3 hedge funds and large institutions have $3.44M invested in Immunovant in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2.43% more ownership
Funds ownership: 0% → 2.43% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Scoggin Management
New York
|
+$2.47M |
| 2 |
Magnetar Financial
Evanston,
Illinois
|
+$494K |
| 3 |
Weiss Asset Management
Boston,
Massachusetts
|
+$494K |
Top Sellers
IMVT Hedge Fund Activity: Q2 2019 in Review
3 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2019, worth a combined $3.44M.
Buyers outnumbered sellers: 3 funds opened new IMVT positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Scoggin Management, opening a new position worth an estimated $2.47M.
- 3 institutional investors held Immunovant (IMVT) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $3.44M of Immunovant stock for Q2 2019.
- 3 funds opened new Immunovant positions in Q2 2019 and 0 closed out, a net change of +3 holders.
- The largest Immunovant buyer in Q2 2019 was Scoggin Management, an estimated $2.47M added.
Based on aggregated 13F filings for Q2 2019.